GPC3 and Leber congenital amaurosis: MAGE-A1 antigen, glypican-3 (GPC3), FRβ, CD44v6, CD133, c-MET, Olfactory receptor 2H1 (OR2H1), CD47, GD2, CD147, prostate stem cell antigen (PSCA), Fibroblast activating protein (FAP), EphA2 and PTK7 are also expected to be targets of CAR in the context of LCa, with preclinical studies completed [190, 195, 203, 204, 208–218] (Fig. 3).